Editas Medicine Reports Incentives to New Chief Financial Officer


Editas Medicine Co., Ltd.

Editas Medicine Co., Ltd.

CAMBRIDGE, Mass., May 18, 2023 (Globe Newswire) — Editas Medicines, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced its newly appointed Chief Financial Officer The award was announced. , Eric Lucera. In connection with Mr. Lucera’s appointment, the Editas Medicine Board of Directors has provided Mr. Lucella with stock of his stock as an incentive for Mr. Lucera to be employed by Editas Medicine pursuant to Nasdaq Listing Rules 5635(c)(4). Approved grant of options. . The stock options allow the purchase of up to 155,800 shares of Editas Medicine common stock at $9.61 per share (the closing price per share of Editas Medicine common stock as reported by the Nasdaq on the date of grant). The fixed period is 4 years. , 25% of his shares will vest on the first anniversary of Mr. Lucera’s commencement of employment, and the remainder will vest equally at the end of each month thereafter. Subject to the continuing working relationship between Mr. Lucella and Editas His Medicine until the applicable vesting date. .

almost editas medicine
As a clinical-stage genome editing company, Editas Medicine will harness the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome editing systems into a robust therapeutic pipeline for people living with serious diseases around the world. The focus is on embedding. Editas Medicine aims to discover, develop, manufacture and commercialize innovative, durable and highly accurate genomic medicines for a wide range of diseases. Editas Medicine is the exclusive licensee of his Cas9 patent assets of the Broad Institute and Harvard University and of his Cas12a patent assets of the Broad Institute for human medicines. For the latest information and scientific publications, please visit www.editasmedicine.com.

CONTACT: Media and Investor Contact Cristi Barnett (617) 401-0113 cristi.barnett@editasmed.com



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *